✦ LIBER ✦

Su1383 Pilot Study of Oral Delivery of Monoclonal Anti-CD3 Antibody (OKT3) in Moderate to Severe Ulcerative Colitis

✍ Scribed by Boden, Elisa K.; Canavan, James B.; Moran, Christopher J.; McCann, Katelyn; Farraye, Francis A.; Ananthakrishnan, Ashwin N.; Yajnik, Vijay; Nguyen, Deanna D.; Korzenik, Joshua R.; Snapper, Scott B.

Book ID: 123504233
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 162 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)61626-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A humanized anti-CD3 monoclonal antibody

A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study

✍ Scott E. Plevy; Bruce A. Salzberg; Miguel Regueiro; William Sandborn; Stephen B. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Efficacy of mycophenolate mofetil in mod

Efficacy of mycophenolate mofetil in moderate to severe ulcerative and Crohn’s colitis—a pilot study

✍ Nizar N Ramzan; Jonathan A Leighton; Russell I Heigh; Cheryl A Moriarty; John R 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 32 KB

Anti-CD4 monoclonal antibody treatment o

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study

✍ Alice B. Gottlieb; Mark Lebwohl; Sophie Shirin; Amelia Sherr; Pat Gilleaudeau; G 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 577 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

251 Phase I study of anti-IgE recombinan

251 Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma

✍ CORREN, J; FROEHLICH, J; SCHOENHOFF, M; SPECTOR, S; RACHELEFSKY, G; SCHANKER, H; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 124 KB

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB